Eli Lilly CEO has stated that Mounjaro could still be listed on Australia’s Pharmaceutical Benefits Scheme (PBS), despite ongoing negotiations surrounding its price. Currently, the medication is not yet accessible through the PBS, leaving many patients with higher out-of-pocket costs. The company is working to reach an agreement with the government regarding a suitable price point for the drug. The CEO’s comments suggest that Eli Lilly remains committed to making Mounjaro available to a wider patient base in Australia. A PBS listing would significantly reduce the cost for individuals requiring the medication, likely for diabetes and weight management. The outcome of these negotiations will determine the accessibility of this potentially impactful treatment for many Australians.